Shanghai, October 15, 2026 — Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited the Medicilon Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon’s Drug Discovery and Pharmaceutical Research Divisions, Dr. Jian Wang, Vice President, and their team extended a warm reception. The two parties engaged in in-depth discussions regarding project progress, data transfer, and strategic priorities for collaboration in the coming year. During the visit, Medicilon presented Revolution Medicines with the “Excellence in Client Partnership Award,” in recognition of the substantial clinical value delivered by Revolution Medicines’ groundbreaking achievements in pan-KRAS drug discovery and development. Acclaim was also extended to the R&D teams of both Medicilon and Revolution Medicines for their years of collaborative endeavors, mutual trust, and mutually beneficial outcomes—an exemplary model of bilateral partnership.
A three-year commitment laid down solid trusted R&D model
Over the past three years, Medicilon’s FTE team has collaborated closely with Revolution Medicines in tackling technical challenges in R&D, consistently prioritizing client needs and pursuing the singular objective of efficiently delivering high-quality molecules to the client. This partnership has established a model of mutual trust and robust CRO-client collaboration.
The Award Ceremony
At the award ceremony, Medicilon presented Revolution Medicines with the “Excellence in Client Partnership Award.” Dr. Maosheng Duan highly commended Revolution Medicines for its pioneering work in advancing KRAS—a target once deemed “undruggable”—and extended congratulations on the U.S. FDA approval in August 2026 of the NDA for daraxonrasib in the treatment of metastatic pancreatic cancer. This milestone will bring hope of survival to vast pancreatic cancer patients, with immeasurable clinical value. The “Excellence in Client Partnership Award” also pays tribute to the trust, dedication, and achievements of both teams over more than three years of collaboration, as well as the confidence in a longer-term and deeper partnership going forward.
In-depth discussions to expand collaboration opportunity
During the discussions, Dr. Jian Wang presented an overview of Medicilon’s development and its integrated R&D platform capabilities spanning from target discovery to IND filing. Medicilon has established a quality system compliant with international standards and holds NMPA and OECD GLP certifications, meets FDA GLP standards, and has obtained AAALAC International accreditation. The company has also built cutting-edge technology service platforms covering ADC/AOC, Target Protein Degradation, RIPTAC, RNAi and Peptide. The two parties engaged in discussions on cross-regional data transfer, project management, and possible expansion of future collaboration. Additionally, both parties fully communicated on how continuously leveraging the efficiency of cross-regional collaborative R&D.
Subsequently, Drs. Liu and Pota toured Medicilon’s R&D laboratories, visiting the chemistry and oligonucleotide labs as well as the API and preclinical research facilities, gaining firsthand insight into Medicilon’s R&D infrastructure and quality management system.
About Revolution Medicines, Inc.:
Revolution Medicines, Inc. (Nasdaq: RVMD) is a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. For more information, visit www.revmed.com.
About Medicilon:
Founded in 2004, Medicilon (Stock Code: 688202.SH) is dedicated to delivering comprehensive preclinical drug R&D services to pharmaceutical enterprises, research institutions, and scientific investigators worldwide. The company has established a one-stop integrated R&D platform encompassing drug discovery, pharmaceutical research, and preclinical research, and has developed service platforms in cutting-edge fields including ADC/AOC, RNAi, peptides (including macrocyclic peptides), TPD, and RIPTAC. The company has instituted a quality system compliant with international standards and has secured GLP certifications from China’s NMPA, the U.S. FDA, and the EU’s OECD, along with AAALAC International accreditation. At present, the company operates approximately 92,000 square meters of R&D laboratory space across Shanghai and Boston. As of the end of June 2026, the company has provided drug R&D services to over 2,000 clients globally and has supported 691 IND approvals.
